Mitochondrial dysfunction in nonalcoholic steatohepatitis (NASH): Are there drugs able to improve it?

Drug Discovery Today: Disease Mechanisms

Volumn 6, Issue 1-4, 2009, Pages

  Begriche, Karima ^a   Knockaert, Laetitia ^b   Massart, Julie ^b   Robin, Marie Anne ^b   Fromenty, Bernard ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 AMINO 2 METHYLPROPIONIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETAINE; CARNITINE; CYTOCHROME P450 2E1; CYTOKINE; FIBRIC ACID DERIVATIVE; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KETONE BODY; LEPTIN; METFORMIN; MITOCHONDRIAL DNA; PENTOXIFYLLINE; REACTIVE OXYGEN METABOLITE; RESVERATROL; ROSIGLITAZONE; SRT 1720; TROLOX C; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADIPOSE TISSUE; ALCOHOL CONSUMPTION; CALORIE; CELL DAMAGE; CELL DEATH; CELL ORGANELLE; CYTOKINE PRODUCTION; DIET; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY YIELD; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENETIC POLYMORPHISM; HISTOLOGY; HUMAN; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; KETOGENESIS; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; RESPIRATORY CHAIN; REVIEW;

EID: 77956616085     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2009.02.002     Document Type: Review

References (74)

1. B.A. Neuschwander-Tetri, and S.H. Caldwell Nonalcoholic steatohepatitis: summary of an AASLD single topic conference Hepatology 37 2003 1202 1219
2. K. Begriche Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it Mitochondrion 6 2006 1 28
3. M.A. Robin Alcohol increases TNF-α and decreases NF-κB to activate hepatic apoptosis in genetically obese mice Hepatology 42 2005 1280 1290
4. Y. Wang Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax J. Nutr. 138 2008 1866 1871
5. S.K. Mantena Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases Free Radic. Biol. Med. 44 2008 1259 1272
6. B.K. Straub Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis Hepatology 47 2008 1936 1946
7. B. Fromenty, and D. Pessayre Inhibition of mitochondrial β-oxidation as a mechanism of hepatotoxicity Pharmacol. Ther. 67 1995 101 154
8. C. Wolfrum, and M. Stoffel Coactivation of Foxa2 through Pgc-1β promotes liver fatty acid oxidation and triglyceride/VLDL secretion Cell Metab. 3 2006 99 110
9. G. Labbe Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies Fundam. Clin. Pharmacol. 22 2008 335 353
10. J.C. Fernandez-Checa, and N. Kaplowitz Hepatic mitochondrial glutathione: transport and role in disease and toxicity Toxicol. Appl. Pharmacol. 204 2005 263 273
11. K.M. Utzschneider, and S.E. Kahn The role of insulin resistance in nonalcoholic fatty liver disease J. Clin. Endocrinol. Metab. 91 2006 4753 4761
12. J.A. Houmard Intramuscular lipid oxidation in obesity Am. J. Physiol. Regul. Integr. Comp. Physiol. 294 2008 R1111 R1116
13. B.A. Neuschwander-Tetri Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone Hepatology 38 2003 1008 1017
14. R. Haeusler, and D. Accili The double life of Irs Cell Metab. 8 2008 7 9
15. 13C-octanoate breath test Am. J. Gastroenterol. 98 2003 2335 2336
16. I. Garcia-Ruiz Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice Hepatology 46 2007 414 423
17. M. Stefanovic-Racic A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels Am. J. Physiol. Endocrinol. Metab. 294 2008 E969 E977
18. K. Begriche Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice Am. J. Physiol. Endocrinol. Metab. 294 2008 E939 E951
19. S.H. Travers Insulin resistance during puberty and future fat accumulation J. Clin. Endocrinol. Metab. 87 2002 3814 3818
20. J.K. Sethi, and A.J. Vidal-Puig Adipose tissue function and plasticity orchestrate nutritional adaptation J. Lipid Res. 48 2007 1253 1262
21. M. Nakamuta The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease Int. J. Mol. Med. 22 2008 663 667
22. W.N. Cong The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice Life Sci. 82 2008 890 983
23. F. Yakaryilmaz Effects of vitamin E treatment on peroxisome proliferator-activated receptor-α expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study Intern. Med. J. 37 2007 229 235
24. M. Guzman Flexibility of zonation of fatty acid oxidation in rat liver Biochem. J. 311 1995 853 860
25. D. Pessayre, and B. Fromenty NASH: a mitochondrial disease J. Hepatol. 42 2005 928 940
26. C. Carter-Kent Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment Am. J. Gastroenterol. 103 2008 1036 1042
27. A. Farhadi Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis Liver Int. 28 2008 1026 1033
28. B. Fromenty The ins and outs of mitochondrial dysfunction in NASH Diabetes Metab. 30 2004 121 138
29. J.B. Dixon Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese J. Hepatol. 39 2003 967 971
30. C. Namikawa Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis J. Hepatol. 40 2004 781 786
31. P. Portincasa Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis Clin. Sci. 111 2006 135 143
32. R.A. Harris Regulation of branched-chain α-keto acid dehydrogenase kinase expression in rat liver J. Nutr. 131 2001 841S 845S
33. T.B. Patel Studies on the regulation of the branched chain alpha-keto acid dehydrogenase in the perfused rat liver J. Biol. Chem. 256 1981 9009 9015
34. S.H. Caldwell The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis Hepatology 46 2007 1101 1107
35. F. Chiappini Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray Lab. Invest. 86 2006 154 165
36. H. Kawahara Mutation of mitochondrial DNA in livers from patients with alcoholic hepatitis and nonalcoholic steatohepatitis Alcohol. Clin. Exp. Res. 31 Suppl. 1 2007 S54 S60
37. M. Flamment Fatty liver and insulin resistance in obese Zucker rats: no role for mitochondrial dysfunction Biochimie 90 2008 1407 1413
38. M. Mari Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis Cell Metab. 4 2006 185 198
39. L.A. Videla Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients Clin. Sci. 106 2004 261 268
40. L. Malaguarnera Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients J. Hepatol. 42 2005 585 591
41. K.J. Woodcroft, and R.F. Novak The role of phosphatidylinositol 3-kinase, Src kinase, and protein kinase A signaling pathways in insulin and glucagon regulation of CYP2E1 expression Biochem. Biophys. Res. Commun. 266 1999 304 307
42. M.A. Robin Ethanol increases mitochondrial cytochrome P450 2E1 in mouse liver and rat hepatocytes FEBS Lett. 579 2005 6895 6902
43. F. Akyüz The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease Dig. Dis. Sci. 52 2007 2359 2367
44. Loomba, R. et al. Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment. Pharmacol. Ther., in press
45. V. Ratziu Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial Gastroenterology 135 2008 100 110
46. C. Fernandez-Miranda A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease Dig. Liver Dis. 40 2008 200 205
47. E.F. Georgescu, and M. Georgescu Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study J. Gastrointest. Liver Dis. 16 2007 39 46
48. C.L. Wang Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children World J. Gastroenterol. 14 2008 1598 1602
49. N.J. Woodyatt The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs Carcinogenesis 20 1999 369 372
50. F.J. Gonzalez, and Y.M. Shah PPARα: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators Toxicology 246 2008 2 8
51. U. Risérus Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men Diabetes 57 2008 332 339
52. L. Puljak Evidence for AMPK-dependent regulation of exocytosis of lipoproteins in a model liver cell line Exp. Cell Res. 314 2008 2100 2109
53. C. Carvalho Metformin promotes isolated rat liver mitochondria impairment Mol. Cell Biochem. 308 2008 75 83
54. S.E. Wiley MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity Proc. Natl. Acad. Sci. U. S. A. 104 2007 5318 5323
55. H.J. Pan Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism Vascul. Pharmacol. 45 2006 65 71
56. E. Oyanagi l-Carnitine suppresses oleic acid-induced membrane permeability transition of mitochondria Cell Biochem. Funct. 26 2008 778 786
57. A. Igoudjil High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice Antivir. Ther. 12 2007 389 400
58. R. Note Mitochondrial and metabolic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments Antimicrob. Agents Chemother. 47 2003 3384 3392
59. C. Maisonneuve Effects of zidovudine, stavudine and β- aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting Antivir. Ther. 9 2004 801 810
60. K. Begriche β-Aminoisobutyric acid prevents diet-induced obesity in mice with partial leptin deficiency Obesity 16 2008 2053 2067
61. A.S. Vrablic Altered mitochondrial function and overgeneration of reactive oxygen species precede the induction of apoptosis by 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine in p53-defective hepatocytes FASEB J. 15 2001 1739 1744
62. O. Lukivskaya Protective effect of ursodeoxycholic acid on liver mitochondrial function in rats with alloxan-induced diabetes: link with oxidative stress Life Sci. 80 2007 2397 2402
63. J.D. Amaral p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis J. Biol. Chem. 282 2007 34250 34259
64. C.M. Rodrigues Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation Cell Death Differ. 6 1999 842 854
65. M. Kiyici Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis Can. J. Gastroenterol. 17 2003 713 718
66. A. Sierksma Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity Diabetes Care 27 2004 184 189
67. L. Englund Ogge Alcohol consumption in relation to metabolic regulation, inflammation, and adiponectin in 64-year-old Caucasian women: a population-based study with a focus on impaired glucose regulation Diabetes Care 29 2006 908 913
68. W. Dunn Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease Hepatology 47 2008 1947 1954
69. N. Barri Metabolic and hepatic effects of chronic ethanol consumption in obese ob/ob mice Int. J. Obes. 31 Suppl. 1 2007 S51
70. J. Shang Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase Acta Pharmacol. Sin. 29 2008 698 706
71. J.C. Milne Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes Nature 450 2007 712 716
72. J.N. Feige Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation Cell Metab. 8 2008 347 358
73. F. Lan SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation J. Biol. Chem. 283 2008 27628 27635
74. Y. Liu A fasting switch modulates gluconeogenesis via activator/coactivator exchange Nature 456 2008 269 273